• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Efficient identification of human immunodeficiency virus type 1 mutants resistant to a protease inhibitor by using a random mutant library.利用随机突变文库高效鉴定对蛋白酶抑制剂耐药的人类免疫缺陷病毒 1 型突变体。
Antimicrob Agents Chemother. 2011 Nov;55(11):5090-8. doi: 10.1128/AAC.00687-11. Epub 2011 Aug 29.
2
Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.关于HIV-1蛋白酶非活性位点突变V77I导致奈非那韦耐药性分子机制的结构研究
BMC Bioinformatics. 2015;16 Suppl 19(Suppl 19):S10. doi: 10.1186/1471-2105-16-S19-S10. Epub 2015 Dec 16.
3
Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.在对安普那韦耐药的1型人类免疫缺陷病毒(HIV-1)中,非切割位点的gag突变使HIV-1易于快速获得对安普那韦的耐药性,但会延迟对其他蛋白酶抑制剂耐药性的产生。
J Virol. 2009 Apr;83(7):3059-68. doi: 10.1128/JVI.02539-08. Epub 2009 Jan 28.
4
Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naïve patients treated with NFV-containing regimens in an HIV clinic cohort.在一家艾滋病诊所队列中,对初治蛋白酶抑制剂的患者采用含奈非那韦(NFV)方案治疗108周随访期内的原发性奈非那韦(NFV)相关耐药突变情况。
J Clin Virol. 2003 Aug;27(3):252-62. doi: 10.1016/s1386-6532(02)00179-8.
5
Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.对奈非那韦的表型交叉耐药性:既往抗逆转录病毒治疗的作用及蛋白酶基因中的突变数量
AIDS Res Hum Retroviruses. 2001 Feb 10;17(3):211-5. doi: 10.1089/088922201750063124.
6
Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.在包含选定蛋白酶突变组合的HIV文库复制过程中突变的持续性。
Antiviral Res. 2004 Mar;61(3):173-80. doi: 10.1016/j.antiviral.2003.10.001.
7
Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.在使用奈非那韦治疗失败的HIV-1感染患者中,蛋白酶抑制剂耐药突变的多样模式。
J Med Virol. 2005 Aug;76(4):447-51. doi: 10.1002/jmv.20381.
8
Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.通过分子动力学模拟理解 HIV-1 蛋白酶奈非那韦耐药突变 D30N 在亚型 B 和 C 中的作用。
J Mol Graph Model. 2010 Sep;29(2):137-47. doi: 10.1016/j.jmgm.2010.05.007. Epub 2010 Jun 11.
9
Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication.一种对奈非那韦(NFV)耐药的1型人类免疫缺陷病毒的分离及分子特征分析,该病毒表现出对NFV依赖的复制增强。
J Virol. 2003 Jan;77(1):318-27. doi: 10.1128/jvi.77.1.318-327.2003.
10
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.人类免疫缺陷病毒2型蛋白酶的天然多态性可加速对蛋白酶抑制剂产生耐药性的时间。
Antimicrob Agents Chemother. 2007 Feb;51(2):604-10. doi: 10.1128/AAC.00870-06. Epub 2006 Nov 20.

引用本文的文献

1
Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant.通过免疫接种带有 VLP 制剂的抗体选择的包膜变体,引导针对 HIV-1 的体液反应朝向 MPER 相邻区域。
PLoS One. 2018 Dec 19;13(12):e0208345. doi: 10.1371/journal.pone.0208345. eCollection 2018.

本文引用的文献

1
Molecular Dynamics Simulations of HIV-1 Protease Suggest Different Mechanisms Contributing to Drug Resistance.HIV-1 蛋白酶的分子动力学模拟提示了导致耐药性的不同机制。
J Chem Theory Comput. 2005 Mar;1(2):315-24. doi: 10.1021/ct049869o.
2
HIV-1 protease mutations and protease inhibitor cross-resistance.HIV-1 蛋白酶突变与蛋白酶抑制剂交叉耐药性。
Antimicrob Agents Chemother. 2010 Oct;54(10):4253-61. doi: 10.1128/AAC.00574-10. Epub 2010 Jul 26.
3
HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals.HIV 持续存在以及 HIV 感染者实现长期无药物缓解的前景。
Science. 2010 Jul 9;329(5988):174-80. doi: 10.1126/science.1191047.
4
Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.基因型耐药对病毒学失败的 HIV-1 感染患者新型抗逆转录病毒药物的临床意义。
Clin Infect Dis. 2010 Mar 15;50(6):872-81. doi: 10.1086/650732.
5
Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance.检测和理解导致 HIV 耐药性的组合突变模式。
Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1321-6. doi: 10.1073/pnas.0907304107. Epub 2010 Jan 11.
6
New developments in HIV drug resistance.艾滋病毒耐药性的新进展。
J Antimicrob Chemother. 2009 Sep;64 Suppl 1:i37-40. doi: 10.1093/jac/dkp258.
7
Transposon-directed base-exchange mutagenesis (TDEM): a novel method for multiple-nucleotide substitutions within a target gene.转座子导向的碱基交换诱变(TDEM):一种在目标基因内进行多核苷酸替换的新方法。
Biotechniques. 2009 Jun;46(7):534-42. doi: 10.2144/000113152.
8
Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.在未经抗逆转录病毒治疗的慢性HIV感染患者中,低丰度耐药病毒变体对治疗结果有显著影响。
J Infect Dis. 2009 Mar 1;199(5):693-701. doi: 10.1086/596736.
9
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.在初治且依从性良好的患者中导致早期治疗失败的耐药性HIV-1少数准种。
Clin Infect Dis. 2009 Jan 15;48(2):239-47. doi: 10.1086/595703.
10
Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.在未接受过抗逆转录病毒治疗的人群中存在少数HIV-1耐药性突变,且这些突变与治疗效果降低有关。
PLoS Med. 2008 Jul 29;5(7):e158. doi: 10.1371/journal.pmed.0050158.

利用随机突变文库高效鉴定对蛋白酶抑制剂耐药的人类免疫缺陷病毒 1 型突变体。

Efficient identification of human immunodeficiency virus type 1 mutants resistant to a protease inhibitor by using a random mutant library.

机构信息

UCLA School of Medicine, Los Angeles, CA 90095, USA.

出版信息

Antimicrob Agents Chemother. 2011 Nov;55(11):5090-8. doi: 10.1128/AAC.00687-11. Epub 2011 Aug 29.

DOI:10.1128/AAC.00687-11
PMID:21876045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3195011/
Abstract

Emergence of drug-resistant mutant viruses during the course of antiretroviral therapy is a major hurdle that limits the success of chemotherapeutic treatment to suppress human immunodeficiency virus type 1 (HIV-1) replication and AIDS progression. Development of new drugs and careful patient management based on resistance genotyping data are important for enhancing therapeutic efficacy. However, identifying changes leading to drug resistance can take years of clinical studies, and conventional in vitro assays are limited in generating reliable drug resistance data. Here we present an efficient in vitro screening assay for selecting drug-resistant variants from a library of randomly mutated HIV-1 strains generated by transposon-directed base-exchange mutagenesis. As a test of principle, we screened a library of mutant HIV-1 strains containing random mutations in the protease gene by using a reporter T-cell line in the presence of the protease inhibitor (PI) nelfinavir (NFV). Analysis of replicating viruses from a single round of infection identified 50 amino acid substitutions at 35 HIV-1 protease residue positions. The selected mutant viruses showed specific resistance to NFV and included most of the known NFV resistance mutations. Therefore, the new assay is efficient for identifying changes leading to drug resistance. The data also provide insights into the molecular mechanisms underlying the development of drug resistance.

摘要

在抗逆转录病毒治疗过程中,耐药突变病毒的出现是一个主要障碍,限制了化学治疗抑制人类免疫缺陷病毒 1 型(HIV-1)复制和艾滋病进展的成功。开发新的药物和基于耐药基因型数据的谨慎患者管理对于提高治疗效果非常重要。然而,确定导致耐药性的变化可能需要多年的临床研究,并且传统的体外检测在产生可靠的耐药性数据方面受到限制。在这里,我们提出了一种有效的体外筛选检测方法,用于从转座子指导的碱基交换诱变产生的随机突变 HIV-1 株文库中选择耐药变体。作为原理的验证,我们在存在蛋白酶抑制剂(PI)奈非那韦(NFV)的情况下,使用报告 T 细胞系筛选了含有蛋白酶基因随机突变的突变 HIV-1 株文库。对一轮感染中复制病毒的分析鉴定了 HIV-1 蛋白酶 35 个残基位置的 50 个氨基酸取代。所选的突变病毒对 NFV 表现出特异性耐药性,并且包括大多数已知的 NFV 耐药突变。因此,新的检测方法可有效识别导致耐药性的变化。这些数据还提供了对耐药性发展的分子机制的深入了解。